Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine

@inproceedings{Funder2013MineralocorticoidRA,
  title={Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine},
  author={John W. Funder},
  booktitle={Integrated blood pressure control},
  year={2013}
}
Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor (MR) antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much more MR-specific. From a marginal role as a potassium-sparing diuretic, spironolactone was shown to be an extraordinarily effective adjunctive agent in the treatment of progressive heart failure, as was eplerenone in subsequent heart failure trials. Neither acts as an aldosterone… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Renin-angiotensin system blockade: Finerenone.

Nephrologie & therapeutique • 2017
View 2 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Regression of ventricular hypertrophy in low renin hypertension patients and primary aldosteronism on low dose spironolactone

Y Ori, A Chagnac, A Korzets
Nephrol Dialys Transpl. February • 2013
View 2 Excerpts

11-deoxycortisol is a corticosteroid hormone in the lamprey.

Proceedings of the National Academy of Sciences of the United States of America • 2010
View 1 Excerpt

Similar Papers

Loading similar papers…